Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Ath – page 133

1 642 clinical trials in Ath, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Ath at a glance
1 642
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 642 trials in Ath

Open in trial search

Study on Milvexian and Drug Combination for Patients Recovering from a Heart Attack

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Janssen Cilag International

Study on Volixibat for Treating Itching in Patients with Primary Biliary Cholangitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Volixibat
  • Sponsor:Mirum Pharmaceuticals Inc.

Study on SOT102 for Patients with Advanced Gastric and Pancreatic Cancer, Alone or with Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:SOTIO Biotech a.s.

Oropharyngeal cancer

Not recruiting

Study on Swallowing and Quality of Life in Advanced Head and Neck Cancer Patients Using Cisplatin and Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Barium Sulfate
  • Sponsor:Institut Jules Bordet

Colitis ulcerative

Not recruiting

Study on Ustekinumab for Children with Moderate to Severe Ulcerative Colitis

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Ustekinumab
  • Sponsor:Janssen Cilag International

Endometrial cancer

Not recruiting

Study of Pembrolizumab with Chemotherapy for High-Risk Endometrial Cancer Patients After Surgery

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel
  • Sponsor:Merck Sharp & Dohme LLC

Study of Pembrolizumab, Paclitaxel, and Bevacizumab for Patients with Platinum-Resistant Recurrent Ovarian Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel
  • Sponsor:Merck Sharp & Dohme LLC

Study on Rifaximin for Delaying Hepatic Encephalopathy in Cirrhosis Patients

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Rifaximin
  • Sponsor:Salix Pharmaceuticals Inc.

Marginal zone lymphoma+1

Not recruiting

Study Comparing Zanubrutinib, Obinutuzumab, and Rituximab with Lenalidomide and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:BeOne Medicines AG

Study on the Safety and Effects of BIIB080 for Patients Aged 50-80 with Mild Cognitive Impairment or Mild Alzheimer's Disease Dementia

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BIIB080
  • Sponsor:Biogen Idec Research Limited

Crohn's disease

Not recruiting

Study on Ustekinumab for Children with Moderate to Severe Crohn's Disease

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Ustekinumab
  • Sponsor:Janssen Cilag International

Study on Valaciclovir to Prevent Congenital CMV Infection in Pregnant Women with First Trimester CMV Infections

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Valaciclovir
  • Sponsor:UZ Leuven

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Ath

What the registry says about research in the country

01 Cardiovascular and Cerebrovascular Research

Clinical research in Ath addresses critical cardiovascular conditions, particularly focusing on cerebrovascular events. Investigations center on acute ischemic stroke and high-risk transient ischemic attack, conditions that represent significant causes of disability and mortality. These studies aim to evaluate novel therapeutic approaches designed to reduce the risk of recurrent ischemic events in patients who have experienced these serious cerebrovascular incidents.

  • Assessment of innovative pharmacological interventions for stroke prevention
  • Evaluation of treatment strategies to minimize recurrent cerebrovascular events
  • Investigation of therapeutic efficacy in acute cerebrovascular conditions
  • Research focused on improving outcomes for patients with transient ischemic attacks

The research underway seeks to establish safer and more effective treatment protocols for individuals at elevated risk of stroke, potentially improving long-term neurological outcomes and quality of life for affected patients.

02 Oncology and Gastrointestinal Cancer Research

Ath hosts clinical investigations in the field of oncology, with particular emphasis on gastrointestinal malignancies. Research efforts concentrate on locally advanced rectal cancer, examining treatment strategies tailored to specific patient populations. These trials explore different approaches to neoadjuvant therapy, which involves treatment administered before surgical intervention, aiming to optimize the balance between treatment effectiveness and patient safety.

  • Comparison of conventional neoadjuvant therapy versus total neoadjuvant therapy approaches
  • Evaluation of treatment efficacy and safety profiles in older cancer populations
  • Investigation of optimal timing and sequencing of chemotherapy and radiation therapy
  • Research on personalized treatment strategies for rectal cancer management

These studies are particularly significant as they address the unique needs of older patients with rectal cancer, seeking to identify treatment regimens that maximize therapeutic benefit while minimizing adverse effects in this vulnerable population.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.